Research note · October 13, 2026
EssilorLuxottica sold more than seven million AI glasses in 2025, including Ray-Ban Meta and Oakley Meta. That is substantial demand for a wearable product. The investment question is how much commercial value comes from the intelligence inside it. [1]
Our view is that three opportunities lead on different dimensions: camera/audio glasses for new hardware demand, actionable health monitoring and coaching for recurring-payment potential, and audio assistance for distribution. The evidence supports that opportunity map; incremental AI revenue and profits remain unresolved. [1] [2] [3] [4] [5] [6]
The distinction matters throughout the investment case. Product sales, membership bookings and medical-monitoring revenue tell us where customers already spend. They leave a harder question: how much additional value does AI create, and who keeps it?
Glasses have commercial scale; their economics need a closer look
The growth is visible in both industry shipments and company revenue. IDC reported approximately 2.25 million global smart-glasses shipments in the first quarter of 2026, up 167% year over year. Separately, EssilorLuxottica said its AI-glasses revenue almost doubled in the second quarter. These are distinct observations, with different periods and denominators. [2] [7]
For investors, the Meta–EssilorLuxottica partnership therefore offers demonstrated commercial exposure. The allocation of profit is less clear. EssilorLuxottica’s 18.6% adjusted operating margin in the first half of 2026 applies to the whole group; the supplied disclosures leave the partners’ profit split and glasses contribution margins unresolved. [1] [7] [8] [9]
The category forecast also contains a tension: rapid unit growth can coexist with much slower revenue growth. Multiplying IDC’s forecast 2030 display-less-glasses shipments by its forecast average selling price gives approximately $6.25 billion of hardware revenue. Against IDC’s $5.1 billion forecast for 2026, that implies about 23% cumulative revenue growth while units roughly double. [2]
Exhibit 1. Forecast unit growth far outpaces revenue growth
IDC’s 2026–2030 display-less-glasses assumptions imply roughly doubling units while hardware revenue grows about 23%.
[2]View data — original input
Original input data for Exhibit 1. Forecast unit growth far outpaces revenue growth; chart filters and transformations do not change this table.| measure | growth | label |
|---|
| Units | 100.7 | 100.7% |
| Revenue | 22.6 | 22.6% |
Source: IDC. Revenue growth is derived from forecast shipments and average selling price; all figures cover display-less glasses. [2]
Those assumptions imply approximately 5.2% annual hardware revenue growth over four years. The distinction between volume and revenue belongs at the center of the investment analysis: a much larger population of devices need not produce a proportionately larger hardware business. [2]
Advanced display products remain a separate commercial case. Meta Ray-Ban Display launched from $799 including the Neural Band. Reuters reported on January 6, 2026 that it had sold 15,000 units in its first quarter of sales. [10] [11]
Accessibility provides a concrete example of what glasses can offer. Meta describes AI-generated explanations of the wearer’s environment and, separately, its Be My Eyes Call a Volunteer feature. One interprets the scene using AI; the other connects the user to human assistance. The commercial opportunity is tangible, although the supplied evidence leaves glasses-specific adoption, retention and outcomes unquantified. [12]
Health has existing payments behind the opportunity
Glasses demonstrate demand for a new product category. Health wearables bring a different attraction: established monitoring businesses and membership relationships. Our view is that actionable monitoring and coaching belong among the leading opportunities because of that recurring-payment potential. The distinction to preserve is between the existing business and the additional value AI might contribute. [4] [5] [6]
Exhibit 2. Monitoring businesses already generate substantial revenue
| Company | Q2 2026 revenue | Year-over-year growth | Gross margin | Sources |
|---|
| Dexcom | $1.308bn | 13% | 63.4% GAAP | [4] |
| iRhythm | $224.2m | 20.1% | 72.8% | [5] |
The two companies show substantial monitoring revenue and gross margins; these figures describe their company-wide quarterly economics. [4] [5]
The demand evidence extends beyond those quarterly results. Abbott reported second-quarter 2026 continuous-glucose-monitor sales growth of 11% on a reported basis and 9.5% on a comparable basis. Dexcom guided to full-year revenue of $5.18–$5.25 billion, which management described as approximately 11–13% growth. [13] [4]
Consumer memberships provide another route to payment. In March 2026, WHOOP said it had more than 2.5 million members. It reported 103% bookings growth during 2025, ending that year at a $1.1 billion bookings run rate. Those are management-reported membership and bookings measures; payment specifically for AI coaching and member retention remain unresolved. [6]
The clinical distinction is equally important. The 2019 Apple Heart Study found a 34% atrial-fibrillation yield among notified participants undergoing follow-up ECG-patch assessment. That result describes a particular follow-up population. General-population diagnostic accuracy and improved clinical outcomes require different evidence. [14]
For investors, these businesses supply evidence of customers paying for monitoring and wearable services. Our opportunity judgment rests on that commercial foundation. It leaves the incremental return from AI open. [4] [5] [6]
Audio offers the broadest distribution
The largest shipment base in this comparison belongs to hearables. IDC forecasts 407.6 million shipments in 2026, against 13.6 million display-less glasses. Dividing those annual category forecasts gives approximately 30 times as many hearables. That is the distribution opportunity; the figures count devices shipped. [3] [2]
Apple supplies two distinct examples of useful functions reaching this form factor. AirPods Pro 3 launched from $249 in the United States with beta Live Translation across selected languages, using iPhone-mediated interaction. The documented hearing-test and hearing-aid example is AirPods Pro 2. [15] [16]
Our view is that audio assistance belongs alongside glasses and health because of this breadth of distribution. Its place in the opportunity map should not be confused with a measured lead in AI revenue. The existing shipment channel is clear; the incremental commercial value of intelligence remains the question. [3] [2]
Deployment and useful features still leave execution risk
Enterprise maintenance and collaboration are already operating wearable applications. Vuzix has described deployed glasses supporting those tasks. Yet its 2025 company results—$6.3 million in revenue and a $1.1 million gross loss—show why deployment alone is an incomplete investment case. The supplied evidence leaves scaled incremental AI returns unresolved. [17] [18]
Consumer products face a practical limit as well: continuous assistance needs energy. Meta advertised up to eight hours of mixed use for Ray-Ban Meta Gen 2. In its September 2025 description, the transition to always-available assistance depended on further battery and energy-efficiency improvements. The mixed-use specification cannot be read as continuous AI runtime. [19]
Standalone general-purpose assistants warrant particular caution. Humane’s reported returns problem and the February 2025 shutdown of its Ai Pin provide a concrete execution warning. We regard that as a reason for skepticism about the category’s commercial challenges, while leaving open the possibility that a future product succeeds. [20] [21]
The next evidence must connect AI to the money
The strongest objection to our opportunity map is also its central limitation: demonstrated wearable demand does not prove AI creates the commercial value. The disclosed glasses sales, monitoring revenue and membership bookings leave incremental AI revenue and profit unseparated. We give that objection substantial weight. [1] [4] [5] [6]
The questions that matter next follow directly from that gap: how much engagement comes from AI, whether customers pay for it, and what remains after the cost of providing it. For glasses, the partner profit split and product contribution margins also matter. For health, commercial adoption and clinical outcomes must remain separate tests. [8] [9] [14]
The opportunity is visible. The additional profit attributable to AI is the part investors still need to see.
Comments